FDA Approves LEUPROLIDE ACETATE — Zydus Pharmaceuticals USA Inc.

# FDA Approves Generic Leuprolide Acetate from Zydus Pharmaceuticals Zydus Pharmaceuticals USA Inc. received FDA approval for generic leuprolide acetate (ANDA215826), marking another entry into the competitive market for this widely-used hormone therapy treatment, which could increase price competition and expand patient access to this essential medication for prostate cancer and endometriosis. The approval strengthens Zydus's portfolio in the oncology and specialty pharmaceuticals segment while potentially pressuring pricing for branded alternatives in a market where multiple generic competitors are now established.